Telomere Shortening in Three Diabetes Mellitus Types in a Mexican Sample

This study aimed to explore the role of telomere length in three different diabetes types: latent autoimmune diabetes of adulthood (LADA), latent autoimmune diabetes in the young (LADY), and type 2 diabetes mellitus (T2DM). A total of 115 patients were included, 72 (62.61%) had LADA, 30 (26.09%) had...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2023-02, Vol.11 (3), p.730
Main Authors: Cuevas Diaz, Pavel, Nicolini, Humberto, Nolasco-Rosales, German Alberto, Juarez Rojop, Isela, Tovilla-Zarate, Carlos Alfonso, Rodriguez Sanchez, Ester, Genis-Mendoza, Alma Delia
Format: Article
Language:English
Subjects:
Autoimmune diseases
Chromosomes
Comorbidity
Diabetes
Diabetes mellitus (non-insulin dependent)
Disease
DNA damage
Health aspects
Hospitals
Hyperglycemia
Insulin
Insulin resistance
Laboratories
Metabolism
Metformin
Mexicans
Oxidative stress
Patients
Statistical analysis
Telomerase
telomere length
telomere shortening
Telomeres
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to explore the role of telomere length in three different diabetes types: latent autoimmune diabetes of adulthood (LADA), latent autoimmune diabetes in the young (LADY), and type 2 diabetes mellitus (T2DM). A total of 115 patients were included, 72 (62.61%) had LADA, 30 (26.09%) had T2DM, and 13 (11.30%) had LADY. Telomere length was measured using real-time Polymerase Chain Reaction. For statistical analysis, we used the ANOVA test, X2 test, and the Mann-Whitney U test. Patients with T2DM had higher BMI compared to LADA and LADY groups, with a BMI average of 31.32 kg/m ( = 0.0235). While the LADA group had more patients with comorbidities, there was not a statistically significant difference ( = 0.3164, = 0.3315, = 0.3742 for each of the previously mentioned conditions). There was a difference between those patients with T2DM who took metformin plus any other oral antidiabetic agent and those who took metformin plus insulin, the ones who had longer telomeres. LADA patients had shorter telomeres compared to T2DM patients but not LADY patients. Furthermore, T2DM may have longer telomeres thanks to the protective effects of both metformin and insulin, despite the higher BMI in this group.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11030730